CF PharmTech was founded in 2007, it is a fully independent, dynamic, integrated, specialty pharmaceutical company focused on the development and manufacturing of products for the treatments of asthma, COPD and allergic rhinitis for the global market. Its mission is to develop high-quality and affordable medicine to help patients achieve effective management care for their respiratory diseases. The headquarters is located in the lakeside of the Caohu District of Suzhou, Jiangsu Province, with many very convenient transportation options available. It only takes thirty minutes by train to Shanghai and four hours by train to Beijing.
Total raised: $205M
Investors 3
Funding Rounds 3
| Date | Series | Amount | Investors |
| 02.07.2020 | Series F | $50M | - |
| 02.01.2020 | Series E | $90M | - |
| 28.08.2017 | Series D | $65M | - |
Mentions in press and media 7
| Date | Title | Description |
| 07.10.2025 | Spot gold prices hit $4,000 for the first time as global uncertainty fuels safe-haven demand | Asia-Pacific markets traded mixed Wednesday. Mainland China and South Korean markets are closed for the holidays. Spot gold prices on Wednesday hit $4,000 for the first time as safe‑haven demand continues to drive the yellow metal’s prices ... |
| 03.07.2020 | CF PharmTech Closes US$50M Series F Financing | CF PharmTech’s manufacturing facility CF PharmTech, Inc., a Suzhou, China-based maker of inhalation products, raised US $50M in Series F financing. This followed its US $90M Series E financing in January of 2020, in total, completing an equ... |
| 02.07.2020 | China’s CF PharmTech bags $50m in Series F round | Premium Chinese respiratory disease-focused pharmaceutical company CF PharmTech, Inc on Thursday said it has raised 360 million yuan ($50 million) in a Series F round of financing from healthcare-focused BioTrack Capital, CICC Capital’s CIC... |
| 02.01.2020 | CF PharmTech Raises $90M in Series E Funding | CF PharmTech’s manufacturing facility CF PharmTech, Inc., a Shuzhou, China-based pharmaceutical company, raised $90m in Series E funding. The round was led by New Alliance Capital with participation from new investors CR-CP Life Science Fun... |
| 02.01.2020 | China’s CF PharmTech raises $90m Series E led by New Alliance Capital | Premium Chinese pharma company CF PharmTech, Inc has raised $90 million in its Series E round led by New Alliance Capital, according to a statement. Continue reading this story with a subscription to DealStreetAsia. Subscribe Already a subs... |
| 29.08.2017 | Term Sheet — Tuesday, August 29 | THREE THINGS Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop Here are 3 interesting stories to start your morning: FLUSH WITH CASH: Leonard Green & Partner will acquire CPA Global,... |
| 28.08.2017 | CF PharmTech Raises $65M in Series D Financing | CF PharmTech, Inc., a Suzhou, China-based specialty pharmaceutical company that develops and manufactures inhalation products, raised $65M in Series D financing. The round was led by Future Industry Investment Fund, a private equity fund ma... |